Plurexa LLC
Publicly observedSeattle, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Seattle | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Plurexa LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | WAV2HG8VLNK4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant12 Apr 2023Publicly observed
NIH SBIR/STTR award: Targeting Myosin to Treat Polycystic Kidney Disease
USD 770,372.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant12 Apr 2023Publicly observed
NIH SBIR/STTR award: Targeting Myosin to Treat Polycystic Kidney Disease
USD 839,264.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.